Back to top
more

BioMarin Pharmaceutical (BMRN)

(Real Time Quote from BATS)

$69.34 USD

69.34
189,282

-0.76 (-1.08%)

Updated Oct 2, 2024 11:14 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

BioMarin (BMRN) Hemophilia Gene Therapy Gets EMA's Speedy Review

The EMA grants accelerated assessment to BioMarin's (BMRN) request for review of valoctocogene roxaparvovec for treating severe hemophilia A.

BioMarin (BMRN) Q1 Earnings Beat, FDA Delays Vosoritide Decision

BioMarin (BMRN) beats estimates for both earnings and revenues in the first quarter of 2021.

BioMarin Pharmaceutical (BMRN) Tops Q1 Earnings and Revenue Estimates

BioMarin (BMRN) delivered earnings and revenue surprises of 75.00% and 9.11%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate BioMarin Pharmaceutical (BMRN) to Report a Decline in Earnings: What to Look Out for

BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioMarin (BMRN) Down 7.7% Since Last Earnings Report: Can It Rebound?

BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

BioMarin (BMRN) Hemophilia Gene Therapy Gets FDA's RMAT Tag

FDA grants RMAT designation to BioMarin's (BMRN) gene therapy for severe hemophilia A, valoctocogene roxaparvovec, after rejecting it last year.

BioMarin (BMRN) Q4 Earnings Beat, 2021 Sales View Dull

BioMarin (BMRN) beats estimates for both earnings and sales in the fourth quarter. Sales guidance for 2021 falls short of investor expectation.

Earnings Preview: BioMarin Pharmaceutical (BMRN) Q4 Earnings Expected to Decline

BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ALXN vs. BMRN: Which Stock Is the Better Value Option?

ALXN vs. BMRN: Which Stock Is the Better Value Option?

ALXN vs. BMRN: Which Stock Should Value Investors Buy Now?

ALXN vs. BMRN: Which Stock Is the Better Value Option?

Stock Market News for Jan 12, 2021

Benchmarks declined from record highs on Monday as investors weighed impact of rise in coronavirus cases and ongoing political turmoil on economic growth.

BioMarin (BMRN) Reveals 1-Year Data on Hemophilia Gene Therapy

BioMarin (BMRN) announces one-year update from GENEr8-1 phase III study, which shows that valoctocogene roxaparvovec significantly reduces annualized bleeding rate (ABR) by 84% in patients with hemophilia A.

ALXN or BMRN: Which Is the Better Value Stock Right Now?

ALXN vs. BMRN: Which Stock Is the Better Value Option?

The Zacks Analyst Blog Highlights: BioMarin Pharmaceutical, uniQure, REGENXBIO and Deciphera Pharmaceuticals

The Zacks Analyst Blog Highlights: BioMarin Pharmaceutical, uniQure, REGENXBIO and Deciphera Pharmaceuticals

4 Biotechs That Could Be Potential Acquisition Targets in 2021

We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2021.

Why Is BioMarin (BMRN) Up 6.1% Since Last Earnings Report?

BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Pfizer (PFE) Begins Phase III Study on Hemophilia Candidate

Pfizer (PFE) doses the first participant in the late-stage BASIS study, currently investigating marstacimab to address severe hemophilia A or B with or without inhibitors.

Intercept's (ICPT) Q3 Loss Wider Than Expected, Sales Beat

Intercept (ICPT) posts a wider loss but beats on sales in the third quarter of 2020.

BioMarin (BMRN) Beats on Q3 Earnings, Lowers Sales View

BioMarin (BMRN) beats estimates for both earnings and sales in the third quarter. The company lowers its sales guidance for 2020.

BioMarin Pharmaceutical (BMRN) Q3 Earnings and Revenues Top Estimates

BioMarin (BMRN) delivered earnings and revenue surprises of 116.00% and 3.62%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate BioMarin Pharmaceutical (BMRN) to Report a Decline in Earnings: What to Look Out for

BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioMarin Pharmaceutical (BMRN) Stock Moves -0.84%: What You Should Know

BioMarin Pharmaceutical (BMRN) closed at $76.88 in the latest trading session, marking a -0.84% move from the prior day.

Earnings Preview: BioMarin Pharmaceutical (BMRN) Q3 Earnings Expected to Decline

BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioMarin (BMRN) Gets FDA Approval for Higher Dose of Palynziq

The FDA approves higher dose (60 mg) of BioMarin's (BMRN) Phenylketonuria drug Palynziq injection. The regulatory nod includes the addition of longer-term efficacy data on Palynziq's label.

Ascendis Progresses With Hypoparathyroidism Drug TransCon PTH

Ascendis Pharma (ASND) reports encouraging preliminary data on its hypoparathyroidism candidate, TransCon PTH. A late-stage study is anticipated to begin soon.